drugset / Trial / NCT04516096
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
NaSingle-groupOpen-labelTreatment
Summary
The protocol is intended to provide extended treatment with AMX0035 to patients who previously participated in an Amylyx sponsored study of AMX0035 for ALS.
Timeline
- Start
- 2020-11-22
- Primary completion
- 2022-12-30
- Completion
- 2023-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sodium Phenylbutyrate | Small molecule | — | Oral |
| Subject | Taurursodiol | Small molecule | — | Oral |